Procter Gamble Health Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Procter & Gamble Health Ltd is ₹ 6273 as of 12 Jun 15:30 . The P/E Ratio of Procter & Gamble Health Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Procter & Gamble Health Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Zydus Lifesciences Ltd for the Mar '26 is ₹ 7721 crore as compare to the Dec '25 revenue of ₹ 6975 crore. This represent the growth of 10.68% The ebitda of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Zydus Lifesciences Ltd for the Mar '26 is ₹ 2291 crore as compare to the Dec '25 ebitda of ₹ 1842 crore. This represent the growth of 24.32% The net profit of Procter & Gamble Health Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 1341 crore over 8 quarters. This represents a CAGR of -4.27% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% The dividend payout of Zydus Lifesciences Ltd changed from 19.16 % to 8.77 % over 5 quarters. This represents a CAGR of -46.48% .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Procter & Gamble Health Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Procter & Gamble Health Ltd or Zydus Lifesciences Ltd?

Market cap of Procter & Gamble Health Ltd is 10,413 Cr while Market cap of Zydus Lifesciences Ltd is 111,123 Cr

What are the key factors driving the stock performance of Procter & Gamble Health Ltd and Zydus Lifesciences Ltd?

The stock performance of Procter & Gamble Health Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Procter & Gamble Health Ltd and Zydus Lifesciences Ltd?

As of June 15, 2026, the Procter & Gamble Health Ltd stock price is INR ₹6273.55. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹1104.35.

How do dividend payouts of Procter & Gamble Health Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Procter & Gamble Health Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.